Pliant Therapeutics PLRX 深 滬
交易中 11-04 10:05:02 美东时间
1.65
-0.020
-1.20%
華盛通- 最 高1.665
- 今 開1.62
- 成交量 5.97万股
- 最 低 1.62
- 昨 收 1.67
- 總市值 1.01亿
- 52周最高 15.80
- 市盈率 靜 --
- 換手率 0.10%
- 52周最低 1.1001
- 委 比 50.11%
- 總股本 6138.82万
- 歷史最高 43.92
- 量 比 2.74
- 振 幅 2.69%
- 歷史最低 1.1001
- 每 手 1
- 風險率 5.09%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Pliant Therapeutics Announces CBO Hans Hull’s Resignation
Pliant Therapeutics ( ($PLRX) ) just unveiled an announcement. On October 20, 2...
10-25 04:59
期权扫描 | 股价三日疯涨600%！Beyond Meat期权成交居全美第一，Call异动大单持续押注
股价三日疯涨600%！Beyond Meat期权成交达252万张居全美第一，获Call大单持续押注；亚马逊期权成交放量35万张，加速部署机器人替代人工>>
10-22 13:39
Pliant Therapeutics Settles Loan with Oxford Finance
Pliant Therapeutics ( ($PLRX) ) has provided an announcement. On October 14, 20...
10-21 06:11
Allogene licensor Cellectis faces patent lawsuit in the U.S.
Cancer drug developer Allogene Therapeutics (NASDAQ:ALLO) announced on Tuesday that its licensor, Cellectis (NASDAQ:CLLS), is facing a lawsuit in the U.S. over allegations of patent infringement relat...
10-14 22:25
JP Morgan Downgrades Pliant Therapeutics to Underweight
JP Morgan analyst Brian Cheng downgrades Pliant Therapeutics (NASDAQ:PLRX) from Neutral to Underweight.
10-10 19:36
Pliant Therapeutics Q2 EPS $(0.71), Inline
Pliant Therapeutics (NASDAQ:PLRX) reported quarterly losses of $(0.71) per share which met the analyst consensus estimate. This is a 22.83 percent increase over losses of $(0.92) per share from the same period last year.
08-08 04:56
Pliant Therapeutics Provides Corporate Update and Reports Second Quarter 2025 Financial Results
Pliant Therapeutics has halted development of bexotegrast in idiopathic pulmonary fibrosis (IPF) following a safety and efficacy analysis. The company continues Phase 1 trials of PLN-101095 in solid tumors, expecting data by year-end. Restructuring efforts to reduce costs have largely been completed, with decreases in R&D and general expenses. As of June 2025, the company held $264.4 million in cash. Pliant remains focused on advancing integrin-b...
08-07 20:05
Pliant ends development of idiopathic pulmonary fibrosis asset bexotegrast
Pliant Therapeutics is ending development of idiopathic pulmonary fibrosis candidate bexotegrast following poor phase 2b/3 results. In March, the company ended the BEACON-IPF trial following a Data Sa...
06-28 04:32
Pliant Therapeutics Discontinues Development Of Bexotegrast In Idiopathic Pulmonary Fibrosis After BEACON-IPF Phase 2b/3 Clinical Trial Review
Bexotegrast development in IPF discontinuedClinical oncology program and early-stage programs continueRecent workforce and operational changes align with next stepsSOUTH SAN FRANCISCO, Calif., June 27, 2025 (GLOBE
06-28 04:12
Pliant Therapeutics Provides Update on BEACON-IPF
Pliant Therapeutics announced the discontinuation of bexotegrast development in idiopathic pulmonary fibrosis (IPF) following unfavorable safety and efficacy results from the BEACON-IPF Phase 2b/3 trial. While the drug showed modest improvements in lung function, it posed increased risks of disease progression and adverse events. The company is focusing on its oncology program, with PLN-101095 entering Phase 1 trials, and leveraging its proprieta...
06-27 20:05
